{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T05:30:11Z","timestamp":1765776611807,"version":"3.48.0"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Benign prostate hyperplasia (BPH), the pathological basis of benign prostatic syndrome (BPS), is an ageing-associated, androgen-driven, non-malignant growth of the prostate, with an inflammatory etiology. It is characterized by hyperproliferation of prostate cells and bothersome lower urinary tract symptoms. Current therapies for BPH provide both symptomatic relief and are disease modifying. However, they are associated with treatment limiting adverse effects. Accordingly, safer and effective alternatives to conventional treatments are required. Prostogrit is a novel, Ayurvedic medicine, indicated for the treatment of BPH. The objective of the current study was to evaluate the pharmacological effects of Prostogrit in rat model of BPH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Ultra high performance liquid chromatography was employed to detect and quantify the phytocompounds present in Prostogrit. BPH was induced in male Sprague Dawley (SD) rats by subcutaneous administration of testosterone propionate (TP) + estradiol benzoate (EB). Rats were administered Prostogrit at the doses of 10, 30, 100 and 300 mg\/kg, twice daily (\n                      <jats:italic>b.i.d.)<\/jats:italic>\n                      . Finasteride administered once daily\n                      <jats:italic>(q.d.)<\/jats:italic>\n                      at the dose of 1 mg\/kg was employed as the method control. The experimental readouts included measurements of the weights of prostate, seminal vesicles and urinary bladder; histological evaluation of prostatic tissue along with mRNA expression of alpha 1A adrenoceptor (\n                      <jats:italic>Adra1a<\/jats:italic>\n                      ) and interleukin 6 (\n                      <jats:italic>Il6<\/jats:italic>\n                      ) genes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Phytochemical analysis of Prostogrit revealed the presence of phytometabolites, namely guggulsterone, gallic acid, 5-hydroxymethylfurfural (5-HMF), methyl gallate, cinnamic acid and piperine. In the\n                      <jats:italic>in vivo<\/jats:italic>\n                      experiment, Prostogrit restored the TP+EB-induced increase in the relative weights of prostate and urinary bladder. It ameliorated the TP+EB-evoked epithelial proliferation, acinar hypertrophy and infiltration of inflammatory cells in the prostate stroma, in a dose-dependent fashion. Additionally, Prostogrit could also suppress the TP+EB-induced increase in the mRNA expression of\n                      <jats:italic>Adra1a<\/jats:italic>\n                      and\n                      <jats:italic>Il6<\/jats:italic>\n                      genes in prostatic tissue.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The findings of the current proof of concept study suggest that Prostogrit has pharmacological effects in an animal model of BPH. Accordingly, it possesses preclinical potential for the pharmacotherapeutic management of BPH, which merits further investigations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2025.1663917","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T05:25:39Z","timestamp":1765776339000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prostogrit mitigates testosterone\/estradiol induced prostatic enlargement\/remodeling in rat model of benign prostatic hyperplasia and fine-tunes prostatic expression of Adra1a and Il6 genes"],"prefix":"10.3389","volume":"16","author":[{"given":"Acharya","family":"Balkrishna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venu","family":"Pamidiboina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meenu","family":"Tomer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rani","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rishabh","family":"Dev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anurag","family":"Varshney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"B1","article-title":"Benign prostatic hyperplasia (BPH) management in the primary care setting","volume":"19","author":"Kapoor","year":"2012","journal-title":"Can J Urol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.12.002","article-title":"Does prostate size predict the development of incident lower urinary tract symptoms in men with mild to no current symptoms? Results from the REDUCE trial","volume":"69","author":"Simon","year":"2016","journal-title":"Eur Urol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2007.01956.x","article-title":"\u03b11-Adreno receptor subtypes and lower urinary tract symptoms","volume":"15","author":"Schwinn","year":"2008","journal-title":"Int J Urol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-002-0248-5","article-title":"Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia","volume":"19","author":"Bartsch","year":"2002","journal-title":"World J Urol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1159\/000496289","article-title":"Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement: A mini-review","volume":"65","author":"Madersbacher","year":"2019","journal-title":"Gerontology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/bju.15229","article-title":"Benign prostatic hyperplasia - what do we know","volume":"127","author":"Devlin","year":"2021","journal-title":"BJU Int"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.diff.2011.04.006","article-title":"Androgens and estrogens in benign prostatic hyperplasia: past, present and future","volume":"82","author":"Nicholson","year":"2011","journal-title":"Differentiation"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2020.113703","article-title":"Curcuma oil ameliorates benign prostatic hyperplasia through suppression of the nuclear factor-kappa B signaling pathway in rats","volume":"279","author":"Wang","year":"2021","journal-title":"J Ethnopharmacol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-7568(22)00213-6","article-title":"The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"3","author":"Awedew","year":"2022","journal-title":"Lancet Heal Longev"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2016.168","article-title":"Inflammatory mediators in the development and progression of benign prostatic hyperplasia","volume":"13","author":"De Nunzio","year":"2016","journal-title":"Nat Rev Urol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/pros.10340","article-title":"Dutasteride, the dual 5\u03b1-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line","volume":"58","author":"Lazier","year":"2004","journal-title":"Prostate"},{"key":"B12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2165\/00003495-199957010-00002","article-title":"Alpha-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia","volume":"57","author":"Cooper","year":"1999","journal-title":"Drugs"},{"key":"B13","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/s0090-4295(03)00471-0","article-title":"Lower urinary tract symptoms\/benign prostatic hyperplasia: minimizing morbidity caused by treatment","volume":"62","author":"Schulman","year":"2003","journal-title":"Urology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2174\/1389557516666160621103817","article-title":"Phytotherapeutic agents for benign prostatic hyperplasia: an overview","volume":"17","author":"Sharma","year":"2017","journal-title":"Mini Rev Med Chem"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00403","article-title":"Upregulation of oxytocin receptor in the hyperplastic prostate","volume":"9","author":"Li","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jsbmb.2014.09.026","article-title":"The prevention and treatment effects of tanshinone IIA on oestrogen\/androgen-induced benign prostatic hyperplasia in rats","volume":"145","author":"Wang","year":"2015","journal-title":"J Steroid Biochem Mol Biol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J Basic Clin Pharm"},{"key":"B18","doi-asserted-by":"publisher","first-page":"7S","DOI":"10.1177\/0192623312438738","article-title":"International harmonization of toxicologic pathology nomenclature: an overview and review of basic principles","volume":"40","author":"Mann","year":"2012","journal-title":"Toxicol Pathol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2-\u0394\u0394CT method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00658","article-title":"Efficacy and side effects of drugs commonly used for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia","volume":"11","author":"Zhao-Jun","year":"2020","journal-title":"Front Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/ijir.2008.55","article-title":"Pathology of benign prostatic hyperplasia","volume":"20","author":"Roehrborn","year":"2008","journal-title":"Int J Impot Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2008.01.034","article-title":"Evaluation of prostatitis in autopsied prostates\u2013is chronic inflammation more associated with benign prostatic hyperplasia or cancer","volume":"179","author":"Delongchamps","year":"2008","journal-title":"J Urol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/diseases13020053","article-title":"Oxidative stress in benign prostatic hyperplasia: mechanisms, clinical relevance and therapeutic perspectives","volume":"13","author":"Kaltsas","year":"2025","journal-title":"Diseases"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000139539.94828.29","article-title":"Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia","volume":"172","author":"Andriole","year":"2004","journal-title":"J Urol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.21037\/tau-22-690","article-title":"5-alpha reductase inhibitors use in prostatic disease and beyond","volume":"12","author":"Chislett","year":"2023","journal-title":"Transl Androl Urol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.766594","article-title":"The efficacy and safety of alpha-1 blockers for benign prostatic hyperplasia: an overview of 15 systematic reviews","volume":"29","author":"Yuan","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e0203479","DOI":"10.1371\/journal.pone.0203479","article-title":"Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis","volume":"13","author":"Kim","year":"2018","journal-title":"PloS One"},{"key":"B28","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/MOU.0b013e32834d9bfd","article-title":"\u03b1-Blockers for benign prostatic hyperplasia: the new era","volume":"22","author":"Lepor","year":"2012","journal-title":"Curr Opin Urol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2009.09.037","article-title":"Lauric acid and myristic acid prevent testosterone induced prostatic hyperplasia in rats","volume":"626","author":"Veeresh Babu","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/iju.13018","article-title":"Effect of 4-chloro-7-trifluoromethyl-10H-benzo[4,5]furo[3,2-b]indole-1-carboxylic acid on the intraurethral pressure in a rat model of benign prostatic hyperplasia","volume":"23","author":"Choi","year":"2016","journal-title":"Int J Urol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S164049","article-title":"Additive effect of oral LDD175 to tamsulosin and finasteride in a benign prostate hyperplasia rat model","volume":"12","author":"Choi","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/5059267","article-title":"Effects of qianlie tongqiao capsule on bladder weight and growth factors in bladder tissue of rats with testosterone-induced benign prostatic hyperplasia","volume":"2018","author":"Zhao","year":"2018","journal-title":"Evidence-Based Complement Altern Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/978-3-642-16499-6_14","article-title":"\u03b1(1)-Adrenoceptors in the urinary tract","volume":"202","author":"Yamada","year":"2011","journal-title":"Handb Exp Pharmacol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.117048","article-title":"The \u03b11-adrenoceptor-mediated human hyperplastic prostate cells proliferation is impaired by EGF receptor inhibition","volume":"239","author":"Nascimento-Viana","year":"2019","journal-title":"Life Sci"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(17)56980","article-title":"Patterns of inflammation in prostatic hyperplasia: a histologic and bacteriologic study","volume":"121","author":"Kohnen","year":"1979","journal-title":"J Urol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/aja.2011.154","article-title":"Influence of immune inflammation on androgen receptor expression in benign prostatic hyperplasia tissue","volume":"14","author":"Wu","year":"2012","journal-title":"Asian J Androl"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2007.06910.x","article-title":"Does intraprostatic inflammation have a role in the pathogenesis and progression of benign prostatic hyperplasia","volume":"100","author":"Mishra","year":"2007","journal-title":"BJU Int"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3889\/oamjms.2019.548","article-title":"The expression of transforming growth factor beta-1 and interleukin-6 on human prostate: prostate hyperplasia and prostate cancer","volume":"7","author":"Afdal","year":"2019","journal-title":"Open Access Maced J Med Sci"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2014.09.025","article-title":"Abacopteris penangiana exerts testosterone-induced benign prostatic hyperplasia protective effect through regulating inflammatory responses, reducing oxidative stress and anti-proliferative","volume":"157","author":"Yang","year":"2014","journal-title":"J Ethnopharmacol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.2174\/1389557518666180330114010","article-title":"Probing gallic acid for its broad spectrum applications","volume":"18","author":"Choubey","year":"2018","journal-title":"Mini Rev Med Chem"},{"key":"B41","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jep.2019.01.038","article-title":"Cynomorium songaricum Rupr demonstrates phytoestrogenic or phytoandrogenic like activities that attenuates benign prostatic hyperplasia via regulating steroid 5-\u03b1-reductase","volume":"235","author":"Tao","year":"2019","journal-title":"J Ethnopharmacol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-0120","article-title":"Guggulsterone-induced apoptosis in human prostate cancer cells is caused by reactive oxygen intermediate-dependent activation of c-Jun NH 2-terminal kinase","volume":"67","author":"Singh","year":"2007","journal-title":"Cancer Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1002\/ptr.6855","article-title":"Piperine: A review of its biological effects","volume":"35","author":"Haq","year":"2021","journal-title":"Phyther Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2013.04.001","article-title":"Screening of target compounds from Fructus Piperis using high \u03b11A adrenoreceptor expression cell membrane chromatography online coupled with high performance liquid chromatography tandem mass spectrometry","author":"Han","year":"2013","journal-title":"J Pharm BioMed Anal"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.fbio.2023.103539","article-title":"Assessment of the in-vitro toxicity and in-vivo therapeutic capabilities of Juglans regia on human prostate cancer and prostatic hyperplasia in rats","volume":"57","author":"Stefanucci","year":"2024","journal-title":"Food Biosci"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106849","article-title":"Methyl gallate: Review of pharmacological activity","volume":"194","author":"Liang","year":"2023","journal-title":"Pharmacol Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2007.09.026","article-title":"Inhibitory effect of traditional Chinese medicine Zi-Shen Pill on benign prostatic hyperplasia in rats","volume":"115","author":"Sun","year":"2008","journal-title":"J Ethnopharmacol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.11.005","article-title":"Comparison of Murraya koenigii- and Tribulus terrestris-based oral formulation versus tamsulosin in the treatment of benign prostatic hyperplasia in men aged >50 years: a double-blind, double-dummy, randomized controlled trial","volume":"33","author":"Sengupta","year":"2011","journal-title":"Clin Ther"},{"key":"B49","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12967-020-02684-3","article-title":"Improvement of urinary tract symptoms and quality of life in benign prostate hyperplasia patients associated with consumption of a newly developed whole tomato-based food supplement: a phase II prospective, randomized double-blinded, placebo-controlled study","volume":"19","author":"Cormio","year":"2021","journal-title":"J Transl Med"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1663917\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T05:25:40Z","timestamp":1765776340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1663917\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":49,"alternative-id":["10.3389\/fendo.2025.1663917"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1663917","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"article-number":"1663917"}}